Xarelto

Bayer HealthCare has launched Xarelto (rivaroxaban) for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.

PHARMACOLOGY

Rivaroxaban is a highly selective direct factor Xa inhibitor, with oral bioavailability, that interrupts the intrinsic and extrinsic blood coagulation pathway, inhibiting both thrombin formation and development of thrombi.

CLINICAL STUDIES
Two phase III studies,1,2 involving over 4,500 patients undergoing elective hip replacement surgery and over 2,500 patients undergoing elective knee replacement surgery, compared the efficacy of rivaroxaban to enoxaparin for the prevention of venous thromboembolism.

The patients were given oral rivaroxaban 10mg once daily started six to eight hours after surgery, or subcutaneous enoxaparin 40mg given 12 hours before surgery and then 40mg once daily started six to eight hours after surgery.

In both studies, rivaroxaban was significantly more effective than enoxaparin in reducing total events of venous thromboembolism and all cause mortality.

The number of major bleeding episodes, the main safety outcome, was comparable for patients treated with rivaroxaban and enoxaparin.

View Xarelto drug record

REFERENCES
1. Eriksson B, Borris L, Friedman R et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. NEJM 2008; 358: 2765-75.
2. Lassen M, Ageno W, Borris L et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. NEJM 2008; 358: 2776-86.

Further information: Bayer HealthCare

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted
MIMSconnect

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)